Early Phase 1 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to sign a consent form and attend follow-up appointments
- People aged 18 or older
- People who have been diagnosed with Type 1 or Type 2 diabetes and have a specific type of eye condition called diabetic macular edema (DME), where fluid causes swelling at the centre of the retina
- People whose retinal swelling measurement (called central subfield thickness) is at or above a certain level (300 μm) in the eye being studied, as measured at the screening visit
- People whose vision in the study eye falls within a specific range on a standard eye chart test (confirm with trial site for exact detail)
- People who have received a type of eye injection treatment called anti-VEGF therapy within the past 12 months and showed a meaningful improvement from it
- People who are able to use effective contraception from the screening period until the last follow-up visit, if they or their partner could become pregnant
Who may not be able to join:
- People who have an advanced form of diabetic eye disease called active proliferative diabetic retinopathy
- People who have abnormal new blood vessel growth on the iris (coloured part of the eye) in the study eye at the time of screening
- People who have had retinal laser treatment in the study eye within the 3 months before screening
- People who have previously had gene therapy in the study eye
- People whose study eye was treated with a specific steroid implant (Ozurdex®) within the 6 months before screening
- People who have received anti-VEGF treatment given through the whole body (such as by injection or infusion into the bloodstream) within the 3 months before screening
- People who have taken part in another clinical trial or received an experimental treatment, device, or therapy within 3 months before screening (or longer, depending on the treatment involved)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 02136126254
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Adverse events and serious adverse events in the eyes and throughout the body within 364 days after LX111 treatment; Dose Limiting Toxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.